Search

Your search keyword '"Sparano, Joseph A"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Sparano, Joseph A" Remove constraint Author: "Sparano, Joseph A" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
112 results on '"Sparano, Joseph A"'

Search Results

1. Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

2. Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

3. Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

4. Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

5. Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

6. Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

7. A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer

8. Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

9. Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

10. Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

11. Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

12. Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

13. Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

14. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

15. Supplementary Data Table 2 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

16. Data from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

17. Supplementary Data Table 1 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

18. Supplementary Data Table 2 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

19. Supplementary Data Table 1 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

20. Data from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

21. Supplemental table 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

22. Table S1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

23. Supplementary Table 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

25. Supplementary Figure 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

26. Supplementary Table S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

27. Supplementary Figure 1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

28. Supplementary Figure Legends from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

29. Supplementary Figure 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

31. Supplementary Table 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

32. Supplementary Figure 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

33. Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

34. Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

35. Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

36. Supplementary Table 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

38. Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

39. Supplementary Table S3 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

40. Supplementary Table 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

43. Supplementary Figure 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

44. Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

46. Data from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

50. Supplementary Table S4 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Catalog

Books, media, physical & digital resources